<!doctype html><html lang=en-us><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=x-ua-compatible content="IE=edge"><meta name=generator content="Source Themes Academic 4.5.0"><meta name=author content="Swapnil Mishra"><meta name=description content="The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era."><link rel=alternate hreflang=en-us href=https://s-mishra.github.io/publication/nature-delta-21/><meta name=theme-color content="#2962ff"><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.11.2/css/all.min.css integrity="sha256-+N4/V/SbAFiW1MPBCXnfnP9QSN3+Keu+NlB+0ev/YKQ=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin=anonymous><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/github.min.css crossorigin=anonymous title=hl-light><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/styles/dracula.min.css crossorigin=anonymous title=hl-dark disabled><link rel=stylesheet href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap"><link rel=stylesheet href=/css/academic.css><script async src="https://www.googletagmanager.com/gtag/js?id=UA-118959441-1"></script>
<script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}function trackOutboundLink(e){gtag("event","click",{event_category:"outbound",event_label:e,transport_type:"beacon",event_callback:function(){document.location=e}}),console.debug("Outbound link clicked: "+e)}function onClickCallback(e){if(e.target.tagName!=="A"||e.target.host===window.location.host)return;trackOutboundLink(e.target)}gtag("js",new Date),gtag("config","UA-118959441-1",{}),document.addEventListener("click",onClickCallback,!1)</script><link rel=manifest href=/index.webmanifest><link rel=icon type=image/png href=/img/icon-32.png><link rel=apple-touch-icon type=image/png href=/img/icon-192.png><link rel=canonical href=https://s-mishra.github.io/publication/nature-delta-21/><meta property="twitter:card" content="summary_large_image"><meta property="twitter:site" content="@creswapi"><meta property="twitter:creator" content="@creswapi"><meta property="og:site_name" content="Swapnil Mishra"><meta property="og:url" content="https://s-mishra.github.io/publication/nature-delta-21/"><meta property="og:title" content="SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion | Swapnil Mishra"><meta property="og:description" content="The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era."><meta property="og:image" content="https://s-mishra.github.io/img/portrait.jpg"><meta property="twitter:image" content="https://s-mishra.github.io/img/portrait.jpg"><meta property="og:locale" content="en-us"><meta property="article:published_time" content="2022-01-03T09:22:38+05:30"><meta property="article:modified_time" content="2021-11-01T09:22:38+05:30"><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://s-mishra.github.io/publication/nature-delta-21/"},"headline":"SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion","datePublished":"2022-01-03T09:22:38+05:30","dateModified":"2021-11-01T09:22:38+05:30","author":{"@type":"Person","name":"Petra Mlcochova"},"publisher":{"@type":"Organization","name":"Swapnil Mishra","logo":{"@type":"ImageObject","url":"https://s-mishra.github.io/img/icon-512.png"}},"description":"The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era."}</script><title>SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion | Swapnil Mishra</title></head><body id=top data-spy=scroll data-offset=70 data-target=#TableOfContents><aside class=search-results id=search><div class=container><section class=search-header><div class="row no-gutters justify-content-between mb-3"><div class=col-6><h1>Search</h1></div><div class="col-6 col-search-close"><a class=js-search href=#><i class="fas fa-times-circle text-muted" aria-hidden=true></i></a></div></div><div id=search-box><input name=q id=search-query placeholder=Search... autocapitalize=off autocomplete=off autocorrect=off spellcheck=false type=search></div></section><section class=section-search-results><div id=search-hits></div></section></div></aside><nav class="navbar navbar-light fixed-top navbar-expand-lg py-0 compensate-for-scrollbar" id=navbar-main><div class=container><a class=navbar-brand href=/>Swapnil Mishra</a>
<button type=button class=navbar-toggler data-toggle=collapse data-target=#navbar aria-controls=navbar aria-expanded=false aria-label="Toggle navigation">
<span><i class="fas fa-bars"></i></span></button><div class="collapse navbar-collapse" id=navbar><ul class="navbar-nav mr-auto"><li class=nav-item><a class=nav-link href=/#about><span>Home</span></a></li><li class=nav-item><a class=nav-link href=/#featured><span>Featured</span></a></li><li class=nav-item><a class=nav-link href=/#publications><span>Publications</span></a></li><li class=nav-item><a class=nav-link href=/#grants><span>Grants</span></a></li><li class=nav-item><a class=nav-link href=/#teaching><span>Teaching</span></a></li><li class=nav-item><a class=nav-link href=/files/cv.pdf><span>CV</span></a></li><li class=nav-item><a class=nav-link href=/#contact><span>Contact</span></a></li></ul><ul class="navbar-nav ml-auto"><li class=nav-item><a class="nav-link js-search" href=#><i class="fas fa-search" aria-hidden=true></i></a></li><li class=nav-item><a class="nav-link js-dark-toggle" href=#><i class="fas fa-moon" aria-hidden=true></i></a></li></ul></div></div></nav><div class=pub><div class="article-container pt-3"><h1>SARS-CoV-2 B. 1.617. 2 Delta variant replication and immune evasion</h1><div class=article-metadata><div><span><a href=/authors/petra-mlcochova/>Petra Mlcochova</a></span>, <span><a href=/authors/steven-a-kemp/>Steven A Kemp</a></span>, <span><a href=/authors/mahesh-shanker-dhar/>Mahesh Shanker Dhar</a></span>, <span><a href=/authors/others/>others</a></span>, <span><a href=/authors/swapnil-mishra/>Swapnil Mishra</a></span>, <span><a href=/authors/charles-whittaker/>Charles Whittaker</a></span>, <span><a href=/authors/thomas-mellan/>Thomas Mellan</a></span>, <span><a href=/authors/others/>others</a></span>, <span><a href=/authors/samir-bhatt/>Samir Bhatt</a></span>, <span><a href=/authors/seth-flaxman/>Seth Flaxman</a></span>, <span><a href=/authors/leo-c-james/>Leo C James</a></span>, <span><a href=/authors/davide-corti/>Davide Corti</a></span>, <span><a href=/authors/luca-piccoli/>Luca Piccoli</a></span>, <span><a href=/authors/wendy-s-barclay/>Wendy S Barclay</a></span>, <span><a href=/authors/partha-rakshit/>Partha Rakshit</a></span>, <span><a href=/authors/anurag-agrawal/>Anurag Agrawal</a></span>, <span><a href=/authors/ravindra-k-gupta/>Ravindra K Gupta</a></span></div><span class=article-date>November 2021</span></div><div class="btn-links mb-3"><a class="btn btn-outline-primary my-1 mr-1" href=https://www.nature.com/articles/s41586-021-03944-y.pdf target=_blank rel=noopener>PDF</a>
<a class="btn btn-outline-primary my-1 mr-1" href=https://github.com/Steven-Kemp/hospital_india/tree/main/consensus_fasta target=_blank rel=noopener>Code</a>
<a class="btn btn-outline-primary my-1 mr-1" href=https://github.com/Steven-Kemp/hospital_india/tree/main/consensus_fasta target=_blank rel=noopener>Dataset</a>
<a class="btn btn-outline-primary my-1 mr-1" href=https://www.nature.com/articles/s41586-021-03944-y target=_blank rel=noopener>Source Document</a>
<a class="btn btn-outline-primary my-1 mr-1" href=https://doi.org/https://doi.org/10.1038/s41586-021-03944-y target=_blank rel=noopener>DOI</a></div></div><div class=article-container><h3>Abstract</h3><p class=pub-abstract>The B.1.617.2 (Delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha)1. In vitro, B.1.617.2 is sixfold less sensitive to serum neutralizing antibodies from recovered individuals, and eightfold less sensitive to vaccine-elicited antibodies, compared with wild-type Wuhan-1 bearing D614G. Serum neutralizing titres against B.1.617.2 were lower in ChAdOx1 vaccinees than in BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies to the receptor-binding domain and the amino-terminal domain. B.1.617.2 demonstrated higher replication efficiency than B.1.1.7 in both airway organoid and human airway epithelial systems, associated with B.1.617.2 spike being in a predominantly cleaved state compared with B.1.1.7 spike. The B.1.617.2 spike protein was able to mediate highly efficient syncytium formation that was less sensitive to inhibition by neutralizing antibody, compared with that of wild-type spike. We also observed that B.1.617.2 had higher replication and spike-mediated entry than B.1.617.1, potentially explaining the B.1.617.2 dominance. In an analysis of more than 130 SARS-CoV-2-infected health care workers across three centres in India during a period of mixed lineage circulation, we observed reduced ChAdOx1 vaccine effectiveness against B.1.617.2 relative to non-B.1.617.2, with the caveat of possible residual confounding. Compromised vaccine efficacy against the highly fit and immune-evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era.</p><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Type</div><div class="col-12 col-md-9"><a href=/publication/#2>Journal article</a></div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=row><div class=col-md-1></div><div class=col-md-10><div class=row><div class="col-12 col-md-3 pub-row-heading">Publication</div><div class="col-12 col-md-9">Nature (2021)</div></div></div><div class=col-md-1></div></div><div class="d-md-none space-below"></div><div class=space-below></div><div class=article-style></div><div class=share-box aria-hidden=true><ul class=share><li><a href="https://twitter.com/intent/tweet?url=https://s-mishra.github.io/publication/nature-delta-21/&text=SARS-CoV-2%20B.%201.617.%202%20Delta%20variant%20replication%20and%20immune%20evasion" target=_blank rel=noopener class=share-btn-twitter><i class="fab fa-twitter"></i></a></li><li><a href="https://www.facebook.com/sharer.php?u=https://s-mishra.github.io/publication/nature-delta-21/&t=SARS-CoV-2%20B.%201.617.%202%20Delta%20variant%20replication%20and%20immune%20evasion" target=_blank rel=noopener class=share-btn-facebook><i class="fab fa-facebook-f"></i></a></li><li><a href="mailto:?subject=SARS-CoV-2%20B.%201.617.%202%20Delta%20variant%20replication%20and%20immune%20evasion&body=https://s-mishra.github.io/publication/nature-delta-21/" target=_blank rel=noopener class=share-btn-email><i class="fas fa-envelope"></i></a></li><li><a href="https://www.linkedin.com/shareArticle?url=https://s-mishra.github.io/publication/nature-delta-21/&title=SARS-CoV-2%20B.%201.617.%202%20Delta%20variant%20replication%20and%20immune%20evasion" target=_blank rel=noopener class=share-btn-linkedin><i class="fab fa-linkedin-in"></i></a></li><li><a href="https://web.whatsapp.com/send?text=SARS-CoV-2%20B.%201.617.%202%20Delta%20variant%20replication%20and%20immune%20evasion%20https://s-mishra.github.io/publication/nature-delta-21/" target=_blank rel=noopener class=share-btn-whatsapp><i class="fab fa-whatsapp"></i></a></li><li><a href="https://service.weibo.com/share/share.php?url=https://s-mishra.github.io/publication/nature-delta-21/&title=SARS-CoV-2%20B.%201.617.%202%20Delta%20variant%20replication%20and%20immune%20evasion" target=_blank rel=noopener class=share-btn-weibo><i class="fab fa-weibo"></i></a></li></ul></div><div class="media author-card content-widget-hr"><div class=media-body><h5 class=card-title><a href=/authors/petra-mlcochova/></a></h5><ul class=network-icon aria-hidden=true></ul></div></div></div></div><script src=https://cdnjs.cloudflare.com/ajax/libs/jquery/3.4.1/jquery.min.js integrity="sha256-CSXorXvZcTkaix6Yvo6HppcZGetbYMGWSFlBw8HfCJo=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/highlight.min.js integrity="sha256-1zu+3BnLYV9LdiY85uXMzii3bdrkelyp37e0ZyTAQh0=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/highlight.js/9.15.10/languages/r.min.js></script>
<script async defer src="https://maps.googleapis.com/maps/api/js?key=AIzaSyDGqCHkZIA7ZavBfuM-EczgZCVaJvJqUHs"></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/gmaps.js/0.4.25/gmaps.min.js integrity="sha256-7vjlAeb8OaTrCXZkCNun9djzuB2owUsaO72kXaFDBJs=" crossorigin=anonymous></script>
<script>hljs.initHighlightingOnLoad()</script><script>const search_config={indexURI:"/index.json",minLength:1,threshold:.3},i18n={no_results:"No results found",placeholder:"Search...",results:"results found"},content_type={post:"Posts",project:"Projects",publication:"Publications",talk:"Talks"}</script><script id=search-hit-fuse-template type=text/x-template>
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script><script src=https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin=anonymous></script>
<script src=https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin=anonymous></script>
<script src=/js/academic.min.01f68d44d80310e669a1731b68a35481.js></script><div class=container><footer class=site-footer><p class=powered-by>©2023 &#183;
Powered by the
<a href=https://sourcethemes.com/academic/ target=_blank rel=noopener>Academic theme</a> for
<a href=https://gohugo.io target=_blank rel=noopener>Hugo</a>.
<span class=float-right aria-hidden=true><a href=# class=back-to-top><span class=button_icon><i class="fas fa-chevron-up fa-2x"></i></span></a></span></p></footer></div><div id=modal class="modal fade" role=dialog><div class=modal-dialog><div class=modal-content><div class=modal-header><h5 class=modal-title>Cite</h5><button type=button class=close data-dismiss=modal aria-label=Close>
<span aria-hidden=true>&#215;</span></button></div><div class=modal-body><pre><code class="tex hljs"></code></pre></div><div class=modal-footer><a class="btn btn-outline-primary my-1 js-copy-cite" href=# target=_blank><i class="fas fa-copy"></i> Copy</a>
<a class="btn btn-outline-primary my-1 js-download-cite" href=# target=_blank><i class="fas fa-download"></i> Download</a><div id=modal-error></div></div></div></div></div></body></html>